AZN vs BSX: fair value comparison
AstraZeneca PLC and Boston Scientific Corporation · Updated 2026-09-07
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, AZN currently sits closer to the top of our discount ranking. BSX carries the stronger quality grade.
| AZN | BSX | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $156.93 | $47.80 |
| 12-month range | $156.93–$202.39 | $46.73–$101.01 |
| Sector rank | #6 of 113 Healthcare | #9 of 113 Healthcare |
| Quality grade | B | A |
| Momentum grade | — | B |
| Leverage | Moderate | Moderate |
| Margin trend | Expanding | Expanding |
| Revenue growth | Strong | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: AZN fair value analysis · BSX fair value analysis